Therapeutic levels of human protein C in rats after retroviral vector- mediated hepatic gene therapy

Journal of Clinical Investigation

Volumn 101, Issue 12, 1998, Pages 2831-2841

  Cai, Shi Rong ^a   Kennedy, Susan C ^a   Bowling, William M ^a   Flye, M Wayne ^a   Ponder, Katherine Parker ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Box 8125 ^*  (United States)

Author keywords

Antibody; Gene therapy; Liver; Protein C; Retroviral vector

Indexed keywords

CHROMOGENIC SUBSTRATE; PROTEIN C; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DNA DETERMINATION; FULMINATING PURPURA; GENE EXPRESSION; GENE THERAPY; GENETIC TRANSDUCTION; IMMUNOASSAY; IMMUNOPRECIPITATION; LIVER CELL; LIVER REGENERATION; MALE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN C DEFICIENCY; RAT; RETROVIRUS;

EID: 0032525902     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI1880     Document Type: Article

References (77)

1. Reiner, A.P., and E.W. Davie. 1995. Introduction to hemostasis and the vitamin K-dependent coagulation factors. In The Metabolic and Molecular Bases of Inherited Disease. 7th ed. Scriver, C.R., A.L. Beaudet, W.S. Sly, and D. Valle, editors. McGraw Hill Inc., New York. 3181-3221.
2. Reitsma, P.H., F. Bernardi, R.G. Doig, S. Gandrille, J.S. Greengard, H. Ireland, M. Krawczak, B. Lind, G.L. Long, S.R. Poort, et al. 1995. Protein C deficiency: a database of mutations, 1995 update. Thromb. Haemostasis. 73:876-889.
3. Miletich, J., L. Sherman, and G. Broze. 1987. Absence of thrombosis in subjects with heterozygous protein C deficiency. N. Engl. J. Med. 317:991-996.
4. Koster, T., F.R. Rosendaal, E. Briet, J.M. van der Meer, L.P. Colly, P.H. Trienekens, S. Poort, P.H. Reitsma, and J.P. Vanderbroucke. 1995. Protein C deficiency in a controlled series of unselected outpatients: an infrequent but clear risk for venous thrombosis (Leiden thrombophilia study). Blood. 85:2756-2761.
5. Seligsohn, U., A. Berger, M. Abend, L. Rubin, D. Attias, A. Zivelin, and S.I. Rapaport. 1984. Homozygous protein C deficiency manifested by massive venous thrombosis in the newborn. N. Engl. J. Med. 310:559-562.
6. Sills, R.H., R.A. Marlar, R.R. Montgomery, G.N. Deshpande, and J.R. Humbert. 1984. Severe homozygous protein C deficiency. J. Pediatr. 105:409-413.
7. Estelles, A., I. Garcia-Plaza, A. Dasi, J. Aznar, M. Duart, G. Sanz, J.L. Perez-Requejo, F. Espana, C. Jimenez, and G. Abeledo. 1984. Severe inherited "homozygous" protein C deficiency in a newborn infant. Thromb. Haemostasis. 52:53-56.
8. Marciniak, E., H.D. Wilson, and R.A. Marlar. 1985. Neonatal purpura fulminans: a genetic disorder related to the absence of protein C in blood. Blood. 65:15-20.
9. Casella, J.F., F.A. Bontempo, H. Markel, J.H. Lewis, B.J. Zitelli, and T.E. Starzl. 1988. Successful treatment of homozygous protein C deficiency by hepatic transplantation. Lancet. i:435-437.
10. Minford, A.M.B., L.A. Parapia, C. Stainforth, and D. Lee. 1996. Treatment of homozygous protein C deficiency with subcutaneous protein C concentrate. Br. J. Haematol. 93:215-216.
11. Dreyfus, M., M. Masterson, M. David, G.E. Rivard, F.M. Muller, W. Kreuz, T. Beeg, A. Minford, J. Allgrove, J.D. Cohen, et al. 1995. Replacement therapy with a monoclonal antibody purified protein C concentrate in newborns with severe congenital protein C deficiency. Semin. Thromb. Hemostasis. 21:371-381.
12. Muller, F.M., W. Ehrenthal, G. Hafner, and D. Schranz. 1996. Purpura fulminans in severe congenital protein C deficiency: monitoring of treatment with protein C concentrate. Eur. J. Pediatr. 155:20-25.
13. Baliga, V., R. Thwaites, M.L. Tillyer, A., Minford, L. Parapia, and J. Allgrove. 1995. Homozygous protein C deficiency - management with protein C concentrate. Eur. J. Pediatr. 154:534-538.
14. Cassels-Brown, A., A.M.B. Minforn, S.L. Chatfield, and J.A. Bradbury. 1994. Ophthalmic manifestations of neonatal protein C deficiency. Br. J. Ophthalmol. 78:486-487.
15. Branson, H.E., J. Katz, R. Marble, and J.H. Griffin. 1983. Inherited protein C deficiency and coumarin-responsive chronic relapsing purpura fulminans in a newborn infant. Lancet. ii:1165-1168.
16. Hartman, K.R., M. Manco-Johnson, J.S. Rawlings, D.J. Bower, and R.A. Marlar. 1989. Homozygous protein C deficiency: early treatment with warfarin. Am. J. Pediatr. Hematol. Oncol. 11:395-401.
17. Yuen, P., A. Cheung, H.J. Lin, F. Ho, J. Mimuro, N. Yoshida, and N. Aoki. 1986. Purpura fulminans in a Chinese boy with congenital protein C deficiency. Pediatrics. 77:670-676.
18. Garcia-Plaza, I., C. Jimenez-Astorga, D. Borrego, and M.L. Marty. 1985. Coumarin prophylaxis for fulminant purpura syndrome due to homozygous protein C deficiency. Lancet. i:634-635.
19. Auberger, K. 1992. Evaluation of a new protein-C concentrate and comparison of protein-C assays in a child with congenital protein-C deficiency. Ann. Hematol. 64:146-151.
20. Conrad, J., K.A. Bauer, A. Gruber, J.H. Griffin, H.P. Schwartz, M.H. Horellou, M.M. Samama, and R.D. Rosenberg. 1993. Normalization of markers of coagulation activation with a purified protein C concentrate in adults with homozygous protein C deficiency. Blood. 82:1159-1164.
21. Brownlee, G.G. 1995. Prospects for gene therapy for haemophilia A and B. Br. Med. Bull. 51:91-105.
22. Thompson, A.R. 1995. Progress towards gene therapy for the hemophilias. Thromb. Hemostasis. 74:45-51.
23. Lozier, J., and K.M. Brinkhous. 1994. Gene therapy and the hemophilias. J. Am. Med. Assoc. 271:47-51.
24. Ponder, K.P. 1997. Gene delivery for systemic expression. In Gene Therapy in the Cardiovascular System. K.L. March, editor. Kluwar Academic Publishers, Norwell, MA. 395-432.
25. Connelly, S., T.A.G. Smith, G. Dhir, J.M. Gardner, M.G. Mchaffey, K.S. Zaret, A. McClelland, and M. Kaleko. 1995. In vivo gene delivery and expression of physiological levels of functional human factor VIII in mice. Hum. Gene Ther. 6:185-193.
26. Connelly, S., J. Mount, A. Mauser, J.M. Gardner, M. Kaleko, A. McClelland, C.D. Lothrop. 1996. Complete short-term correction of canine hemophilia A by in vivo gene therapy. Blood. 88:3846-3853.
27. Connelly, S., J.M. Gardner, A. McClelland, and M. Kaleko. 1996. High-level tissue-specific expression of functional human factor VIII in mice. Hum. Gene Ther. 7:183-195.
28. Dai, Y., E.M. Schwartz, D. Gu, W.-W. Zhang, N. Sarvetnick, and I.M. Verma. 1995. Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression. Proc. Natl. Acad. Sci. USA. 92:1401-1405.
29. Kay, M.A., C.N. Landen, S.R. Rothenberg, L.A. Taylor, F. Leland, S. Wiehle, B. Fang, D. Bellinger, M. Finegold, A.R. Thompson, et al. 1994. In vivo hepatic gene therapy: complete albeit transient correction of factor IX deficiency in hemophilia B dogs. Proc. Natl. Acad. Sci. USA. 91:2353-2357.
30. Smith, T.A.G., M.G. Mehaffey, D.B. Kayda, S.M. Saunders, S. Yei, B.C. Trapneck, A. McClelland, and M. Kaleko. 1993. Adenovirus mediated expression of therapeutic plasma levels of human Factor IX in mice. Nat. Genet. 5: 397-402.
31. Walter, J., Q. You, J.N. Hagstrom, M. Sands, and K.A. High. 1996. Successful expression of human factor IX following repeat administration of an adenoviral vector in mice. Proc. Natl. Acad. Sci. USA. 93:3056-3061.
32. Perales, J.C., T. Ferkol, H. Beegen, O.D. Ratnoff, and R.W. Hanson. 1994. Gene transfer in vivo: sustained expression of genes introduced into the liver by receptor-targeted uptake. Proc. Natl. Acad. Sci. USA. 91:4086-4090.
33. Wang, J.-M., H. Zheng, M. Blaivas, and K. Kurachi. 1997. Persistent systemic production of human Factor IX in mice by skeletal myoblast-mediated gene transfer: feasibility of repeat application to obtain therapeutic levels Blood. 90:1075-1082.
34. Kay, M.A., S. Rothenberg, D.A. Bellinger, F. Leland, C. Tomin, M.S. Reed, K.M. Brinkhous, and S.L.C. Woo. 1993. In vivo gene therapy of hemophilia B: sustained partial correction in factor IX deficient dogs. Science. 266: 117-119.
35. Dai, Y., M. Roman, R.K. Naviaux, and I.M. Verma. 1992. Gene therapy via primary myoblasts: long-term expression of factor IX protein following transplantation in vivo. Proc. Natl. Acad. Sci. USA. 89:10892-10895.
36. Le, M.T., T. Okuyama, S.-R. Cai, S.C. Kennedy, W. Bowling, M.W. Flye, and K.P. Ponder. 1997. Therapeutic levels of functional human factor X in rats after retroviral-mediated hepatic gene therapy. Blood. 89:1254-1259.
37. Herzog, R.W., J.N. Hagstrom, S.H. Kung, S.J. Tai, J.M. Wilson, K.J. Fisher, and K.A. High. 1997. Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus. Proc. Natl. Acad. Sci. USA. 94:5804-5809.
38. Snyder, R.O., C.H. Miao, G.A. Patijn, S.K. Spratt, O. Danos, D. Nagy, A.M. Gown, B. Winther, L. Meuse, L.K. Cohen, et al. 1997. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. Nat. Genet. 16:270-275.
39. Foster, D., and E.W. Davie. 1984. Characterization of a cDNA coding for human protein C. Proc. Natl. Acad. Sci. USA. 81:4766-4770.
40. 1-antitrypsin in vivo. Hum. Gene Ther. 5:637-645.
41. Miller, A.D., and G.J. Rosman. 1989. Improved retroviral vectors for gene transfer and expression. Biotechniques. 7:980-990.
42. Hafenrichter, D.G., S.D. Rettinger, S.C. Kennedy, X. Wu, M.W. Flye, and K.P. Ponder. 1994. Quantitative evaluation of liver-specific promoters from retroviral vectors after in vivo transduction of hepatocytes. Blood. 84:3394-3404.
43. Markowitz, D., S. Goff, and A. Bank. 1988. Construction and use of a safe and efficient amphotropic packaging cell line. Virology. 167:400-409.
44. Jainchill, J.L., S.A. Aaronson, and G.J. Todoro. 1969. Murine sarcoma and leukemia viruses: assay using clonal lines of contact inhibited mouse cells. J. Virol. 4:549-553.
45. Rettinger, S.D., S.C. Kennedy, X. Wu, D. Hafenrichter, M.W. Flye, and K.P. Ponder. 1994. Liver-directed gene therapy: Quantitative evaluation of promoter elements using in vivo retroviral transduction. Proc. Natl. Acad. Sci. USA. 91:1460-1464.
46. Soriano, P., C. Montgomery, R. Geske, and A. Bradley. 1991. Targeted disruption of the c-src protooncogene leads to osteopetrosis in mice. Cell. 64: 693-702.
47. Harlow, E., and D. Lane. 1988. Immunoassays. In Antibodies: A Laboratory Manual. Cold Spring Harbor Press, Cold Spring Harbor, NY. 553-612.
48. Kotani, H., P.B. Newton, S. Zhang, Y.L. Chiang, E. Otto, L. Weaver, R.M. Blaese, W.F. Anderson, and G.J. McGarrity. 1994. Improved methods of retroviral vector transduction and production for gene therapy. Hum. Gene Ther. 5:19-28.
49. Sambrook, J., E.F. Fritsch, and T. Maniatas. 1989. Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY. 7.71-7.78, 9.16-9.21, 10.13-10.37, and 18.47-18.59.
50. Sweetser, D.A., E.H. Birkenmeier, I.J. Klisek, S. Zollman, R.S. Spark, A.J. Mohandes, A.J. Lusis, and J.I. Gordon. 1987. The human and rodent intestinal fatty acid binding protein genes. A comparative analysis of their structure, expression, and linkage relationships. J. Biol. Chem. 262:16060-16071.
51. Kozak, M. 1991. Structural features in eukaryotic mRNAs that modulate the initiation of translation. J. Biol. Chem. 266:19867-19870.
52. Bowles, N.E., R.C. Eisensmith, R. Mohuidden, M. Pyron, and S.L.C. Woo. 1996. A simple and efficient method for the concentration and purification of recombinant retrovirus for increases hepatocyte transduction in vivo. Hum. Gene Ther. 7:1735-1742.
53. Katsuura, Y., T. Mochizuki, M. Tamura, S. Hoshide, M. Kiyoki, T. Nakagaki, and S. Miyamoto. 1996. Species specificity of anticoagulant activity of activated human protein C. Thromb. Res. 82:146-157.
54. Suzuki, K., Y. Deyashiki, J. Nishioka, and K. Toma. 1989. Protein C inhibitor: structure and function. Thromb. Haemostasis. 61:337-342.
55. Espana, F., V. Vicente, D. Tabernero, I. Scharrer, and J.H. Griffen. 1990. Determination of plasma protein C inhibitor and of two activated protein C-inhibitor complexes in normals and in patients with intravascular coagulation and thrombotic disease. Thromb. Res. 59:593-608.
56. 1-antitrypsin. Thromb. Haemostasis. 62:756-762.
57. Sharon, C., M.C. Tirindelli, P.M. Mannucci, A. Tripodi, G. Mariani, and A. Bianchi. 1986. Homozygous protein C deficiency with moderately severe clinical symptoms. Thromb. Res. 41:483-488.
58. Aiach, M., S. Gandrille, and J. Emmerich. 1995. A review of mutations causing deficiencies of antithrombin, protein C, and protein S. Thromb. Haemostasis. 74:81-89.
59. Pescatore, P., H.M. Horellou, J. Conard, M. Piffoux, P. Van Dreden, A. Ruskone-Fourmestraux, and M. Samama. 1993. Problems of oral anticoagulation in an adult with homozygous protein C deficiency and late onset of thrombosis. Thromb. Haemostasis. 69:311-315.
60. Mohanty, D., H.A. Hassan, P. Neglan, B. Elkof, and K.C. Das. 1995. Protein C deficiency in Kuwait. J. Lab. Clin. Med. 126:373-376.
61. Jalbert, L.R., E.D. Rosen, P. Carmeliet, F.J. Castellino, and D. Collen. 1996. Characterization of the anticoagulant protein C by targeted inactivation in mice. Blood. 90:258a. (Abstr.)
62. 1-antitrypsin cDNA using a retroviral vector. Proc. Natl. Acad. Sci. USA. 84:1050-1054.
63. St. Louis, D., and I.M. Verma. 1988. An alternative approach to somatic cell gene therapy. Proc. Natl. Acad. Sci. USA. 85:3150-3154.
64. Yao, S.-N., and K. Kurachi. 1992. Expression of human factor IX in mice after injection of genetically modified myoblasts. Proc. Natl. Acad. Sci. USA. 89:3357-3361.
65. 131 metabolism in human subjects: demonstration of insulin binding globulin in the circulation of insulin treated subjects. J. Clin. Invest. 35: 170-190.
66. Prout, T.E., and R.B. Katims. 1959. The effect of insulin-binding serum globulin on insulin requirements. Diabetes. 8:425-431.
67. McAdams, G.B., K.R. Knox, D.S. Wilcox, and R. Jensen. 1967. The initial rapid-phase disappearance of intravenous radioinsulin in diabetes. J. Nucl. Med. 8:173-178.
68. Dixon, K., P.D. Exon, and J.M. Malins. 1975. Insulin antibodies and the control of diabetes. Q. J. Med. 176:543-553.
69. Takano, K., K. Shizume, N. Hizuka, A. Okuno, T. Umino, Y. Kobayashi, S. Kusano, H. Nakajima, M. Irie, and I. Hibi. 1986. Treatment of pituitary dwarfism with methionyl human growth hormone in Japan. Endocrinol. Jpn. 33:589-596.
70. Batlle, J., E. Gomez, E. Rendal, J. Torea, E. Loures, M. Couselo, P. Vila, C. Sedano, X. Tusell, M. Magallon, et al. 1996. Antibodies to factor VIII in plasma of patients with hemophilia A and normal subjects. Ann. Hematol. 72: 321-326.
71. Richards, S.M., T.A. Olson, and J.M. McPherson. 1993. Antibody response in patients with Gaucher disease after repeated infusion with macrophage-targeted glucocerebrosidase. Blood. 82:1402-1409.
72. Pastores, G.M., A.R. Sibille, and G.A. Grabowski. 1993. Enzyme therapy in Gaucher Disease type 1: dosage efficacy and adverse effects in 33 patients treated for 6 to 24 months. Blood. 82:408-416.
73. Ponce, E., J. Moskovitz, and G. Grabowski. 1997. Enzyme therapy in Gaucher disease type 1: effect of neutralizing antibodies to acid beta-glucuronidase. Blood. 90:43-48.
74. Bowling, W.M., S.C. Kennedy, S.-R. Cai, J.R. Duncan, M.W. Flye, and K.P. Ponder. 1996. Portal branch occlusion safely facilitates in vivo retroviral vector transduction of rat liver. Hum. Gene Ther. 7:2113-2121.
75. Duncan, J.R., M. Hicks, S.-R. Cai, E.M. Brunt, and K.P. Ponder. 1998. Embolization of portal vein branches induces hepatocyte replication in swine. A potential step in hepatic gene therapy. Radiology. In press.
76. Bosch, A., P.B. McCray, S.M.W. Chang, T.R. Ulish, W.S. Simonet, D.J. Jolly, and B.L. Davidson. 1996. Proliferation induced by keratinocyte growth factor enhances in vivo retroviral vector-mediated gene transfer to mouse hepatocytes. J. Clin. Invest. 98:2683-2687.
77. Patijn, G.A., A. Lieber, D.B. Schwalter, R. Schwall, and M.A. Kay. 1998. Hepatocyte growth factor induces proliferation in vivo and allows for efficient retroviral vector transfer in mice. In Keystone Meeting: Molecular and Cellular Biology of Gene Therapy 52. E.G. Nobel and I. Verma, editors.